Sinclair Pharma (XPAR:SPH) Debt-to-Equity : 0.21 (As of Jun. 2018)

View and export this data going back to . Start your Free Trial

What is Sinclair Pharma Debt-to-Equity?

Sinclair Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was €0.00 Mil. Sinclair Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was €20.68 Mil. Sinclair Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2018 was €101.08 Mil. Sinclair Pharma's debt to equity for the quarter that ended in Jun. 2018 was 0.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sinclair Pharma's Debt-to-Equity or its related term are showing as below:

XPAR:SPH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.1 Max: 0.49
Current: 0.21

During the past 13 years, the highest Debt-to-Equity Ratio of Sinclair Pharma was 0.49. The lowest was 0.00. And the median was 0.10.

XPAR:SPH's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.3 vs XPAR:SPH: 0.21

Sinclair Pharma Debt-to-Equity Historical Data

The historical data trend for Sinclair Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinclair Pharma Debt-to-Equity Chart

Sinclair Pharma Annual Data

Trend

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Dec17

Debt-to-Equity

Get a 7-Day Free Trial

0.12

0.11

0.46

0.49

0.05

Sinclair Pharma Semi-Annual Data
	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Jun17	Dec17	Jun18
Debt-to-Equity	Get a 7-Day Free Trial															-	-	0.03	0.05	0.21

Competitive Comparison of Sinclair Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Sinclair Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinclair Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sinclair Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sinclair Pharma's Debt-to-Equity falls into.

Sinclair Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sinclair Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.177	+	4.262)	/	112.345
	=	0.05

Sinclair Pharma's Debt to Equity Ratio for the quarter that ended in Jun. 2018 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	20.677)	/	101.083
	=	0.20

Sinclair Pharma (XPAR:SPH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sinclair Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sinclair Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinclair Pharma (XPAR:SPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sinclairispharma.com

Sinclair Pharma PLC is a United Kingdom-based specialty pharmaceutical company focused on Dermatology, in particular, Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on key emerging markets through long-term multi-product, multi-country, sales & marketing and distribution deals with key strategic partners. The Company's reportable operating segments are International Operations, France, Italy, Germany, UK, and Spain.